FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3042365413> ?p ?o ?g. }

• W3042365413 endingPage "43" @default.
• W3042365413 startingPage "37" @default.
• W3042365413 abstract "Background: Animal studies have shown that a leukocyte influx precedes the development of bronchopulmonary dysplasia (BPD) in premature sheep. The CXC chemokine receptor 2 (CXCR2) pathway has been implicated in the pathogenesis of BPD because of the predominance of CXCR2 ligands in tracheal aspirates of preterm infants who later developed BPD.Purpose: To test the effect of CXCR2 antagonist on postnatal systemic and pulmonary inflammation and alveolarization in a newborn Sprague-Dawley rat model of BPD.Methods: Lipopolysaccharide (LPS) was injected intraperitoneally (i.p.) into the newborn rats on postnatal day 1 (P1), P3, and P5 to induce systemic inflammation and inhibit alveolarization. In the same time with LPS administration, CXCR2 antagonist (SB-265610) or vehicle was injected i.p. to investigate whether CXCR2 antagonist can alleviate the detrimental effect of LPS on alveolarization by attenuating inflammation. On P7 and P14, bronchoalveolar lavage fluid (BALF) and peripheral blood (PB) were collected from the pups. To assess alveolarization, mean cord length and alveolar surface area were measured on 4 random nonoverlapping fields per animal in 2 distal lung sections at ×100 magnification.Results: Early postnatal LPS administration significantly increased neutrophil counts in BALF and PB and inhibited alveolarization, which was indicated by a greater mean cord length and lesser alveolar surface area. CXCR2 antagonist significantly attenuated the increase of neutrophil counts in BALF and PB and restored alveolarization as indicated by a decreased mean cord length and increased alveolar surface area in rat pups exposed to early postnatal systemic LPS.Conclusion: CXCR2 antagonist preserved alveolarization by alleviating pulmonary and systemic inflammation induced by early postnatal systemic LPS administration. These results suggest that CXCR2 antagonist can be considered a potential therapeutic agent for BPD that results from disrupted alveolarization induced by inflammation." @default.
• W3042365413 created "2020-07-23" @default.
• W3042365413 creator A5055980173 @default.
• W3042365413 creator A5088442188 @default.
• W3042365413 date "2021-01-15" @default.
• W3042365413 modified "2023-09-25" @default.
• W3042365413 title "The protective effect of CXC chemokine receptor 2 antagonist on experimental bronchopulmonary dysplasia induced by postnatal systemic inflammation" @default.
• W3042365413 cites W1496078232 @default.
• W3042365413 cites W1585888204 @default.
• W3042365413 cites W182126834 @default.
• W3042365413 cites W1857797615 @default.
• W3042365413 cites W1964294676 @default.
• W3042365413 cites W1979891753 @default.
• W3042365413 cites W1999194263 @default.
• W3042365413 cites W2002963538 @default.
• W3042365413 cites W2004504353 @default.
• W3042365413 cites W2010173630 @default.
• W3042365413 cites W2010745090 @default.
• W3042365413 cites W2039137468 @default.
• W3042365413 cites W2050684121 @default.
• W3042365413 cites W2052456731 @default.
• W3042365413 cites W2059125534 @default.
• W3042365413 cites W2061010331 @default.
• W3042365413 cites W2072229464 @default.
• W3042365413 cites W2078568464 @default.
• W3042365413 cites W2081989923 @default.
• W3042365413 cites W2083079105 @default.
• W3042365413 cites W2089288497 @default.
• W3042365413 cites W2113740477 @default.
• W3042365413 cites W2116108820 @default.
• W3042365413 cites W2123718444 @default.
• W3042365413 cites W2162503073 @default.
• W3042365413 cites W2164401185 @default.
• W3042365413 cites W2164673866 @default.
• W3042365413 cites W2265022799 @default.
• W3042365413 cites W2317266832 @default.
• W3042365413 cites W4211114070 @default.
• W3042365413 cites W4236162659 @default.
• W3042365413 doi "https://doi.org/10.3345/cep.2020.00381" @default.
• W3042365413 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7806409" @default.
• W3042365413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32683807" @default.
• W3042365413 hasPublicationYear "2021" @default.
• W3042365413 type Work @default.
• W3042365413 sameAs 3042365413 @default.
• W3042365413 citedByCount "3" @default.
• W3042365413 countsByYear W30423654132022 @default.
• W3042365413 countsByYear W30423654132023 @default.
• W3042365413 crossrefType "journal-article" @default.
• W3042365413 hasAuthorship W3042365413A5055980173 @default.
• W3042365413 hasAuthorship W3042365413A5088442188 @default.
• W3042365413 hasBestOaLocation W30423654131 @default.
• W3042365413 hasConcept C126322002 @default.
• W3042365413 hasConcept C12823836 @default.
• W3042365413 hasConcept C13373296 @default.
• W3042365413 hasConcept C142724271 @default.
• W3042365413 hasConcept C150903083 @default.
• W3042365413 hasConcept C170493617 @default.
• W3042365413 hasConcept C203014093 @default.
• W3042365413 hasConcept C207001950 @default.
• W3042365413 hasConcept C25938499 @default.
• W3042365413 hasConcept C2776252253 @default.
• W3042365413 hasConcept C2776885963 @default.
• W3042365413 hasConcept C2776914184 @default.
• W3042365413 hasConcept C2777714996 @default.
• W3042365413 hasConcept C2777961210 @default.
• W3042365413 hasConcept C2778122271 @default.
• W3042365413 hasConcept C2778376644 @default.
• W3042365413 hasConcept C2778721537 @default.
• W3042365413 hasConcept C2779234561 @default.
• W3042365413 hasConcept C54355233 @default.
• W3042365413 hasConcept C71924100 @default.
• W3042365413 hasConcept C84913492 @default.
• W3042365413 hasConcept C86803240 @default.
• W3042365413 hasConceptScore W3042365413C126322002 @default.
• W3042365413 hasConceptScore W3042365413C12823836 @default.
• W3042365413 hasConceptScore W3042365413C13373296 @default.
• W3042365413 hasConceptScore W3042365413C142724271 @default.
• W3042365413 hasConceptScore W3042365413C150903083 @default.
• W3042365413 hasConceptScore W3042365413C170493617 @default.
• W3042365413 hasConceptScore W3042365413C203014093 @default.
• W3042365413 hasConceptScore W3042365413C207001950 @default.
• W3042365413 hasConceptScore W3042365413C25938499 @default.
• W3042365413 hasConceptScore W3042365413C2776252253 @default.
• W3042365413 hasConceptScore W3042365413C2776885963 @default.
• W3042365413 hasConceptScore W3042365413C2776914184 @default.
• W3042365413 hasConceptScore W3042365413C2777714996 @default.
• W3042365413 hasConceptScore W3042365413C2777961210 @default.
• W3042365413 hasConceptScore W3042365413C2778122271 @default.
• W3042365413 hasConceptScore W3042365413C2778376644 @default.
• W3042365413 hasConceptScore W3042365413C2778721537 @default.
• W3042365413 hasConceptScore W3042365413C2779234561 @default.
• W3042365413 hasConceptScore W3042365413C54355233 @default.
• W3042365413 hasConceptScore W3042365413C71924100 @default.
• W3042365413 hasConceptScore W3042365413C84913492 @default.
• W3042365413 hasConceptScore W3042365413C86803240 @default.
• W3042365413 hasFunder F4320316485 @default.
• W3042365413 hasIssue "1" @default.
• W3042365413 hasLocation W30423654131 @default.

• next